SECOX as Neoadjuvant Therapy in Patients With Locally Advanced HCC

A Combination of Sorafenib, Capecitabine and Oxaliplatin (SECOX) as Neoadjuvant Therapy in Patients With Locally Advanced Hepatocellular Carcinoma: A Phase II Study

The purpose of this study is to evaluate the resectability after treatment with SECOX (sorafenib, capecitabine, oxaliplatin) as neoadjuvant therapy in patients with locally advanced hepatocellular carcinoma

Inclusion Criteria:

• HCC confined to single lobe of non-cirrhotic liver (locally advanced) and not suitable for surgery or loco-regional therapies at the time of study entry, but can become resectable after treatment
• Diagnosis of HCC confirmed by histology
• Child-Pugh class A cirrhosis with adequate remnant liver parenchyma
• Measurable disease
• Fit enough to undergo surgery to resect the primary liver tumour

Exclusion Criteria:

• Prior systemic therapy for HCC
• Presence of extrahepatic metastasis
• History of liver transplantation
• Peripheral sensory neuropathy with functional impairment
• Uncontrolled hypertension/ cardiac disease